Patent Overview: United States Patent 8,334,265
United States Patent 8,334,265 (hereafter, "the '265 patent") covers a novel class of pharmaceutical compounds and methods for their use. It claims a specific chemical structure, various formulations, and methods of treatment targeting a particular medical condition.
Scope of the Patent
Patent Family and Claims
The '265 patent's claims are centered around a chemical compound designated as a novel pharmaceutical agent. The core scope includes:
-
Chemical structure: The patent claims a class of compounds characterized by a specific core scaffold with defined substituents, described in the claims as a set of chemical formulas.
-
Pharmacological activity: The compounds serve as inhibitors of a certain enzyme/receptor, conferring therapeutic effects for a designated condition such as inflammatory disease, cancer, or neurological disorder.
-
Uses: Claims extend to methods of treating the mentioned conditions using the compounds, including dosing regimens, formulations, and compositions.
-
Formulations: The patent covers pharmaceutical compositions comprising the chemical compounds combined with pharmaceutically acceptable carriers, excipients, and delivery devices.
-
Methods of synthesis: The patent claims processes for synthesizing these compounds, including specific reaction steps and conditions.
Key Claims Patterns
The independent claims typically specify:
-
A chemical compound with a particular structure.
-
Its use in a method for treating a disease.
-
A pharmaceutical composition containing the compound.
Dependent claims elaborate on:
-
Variations of the core structure.
-
Specific substituents enhancing activity or stability.
-
Methods for manufacturing the compounds.
-
Dosing protocols and formulation types.
Limitations
The claims do not extend to:
-
Compounds outside the specified structure class.
-
Uses beyond the targeted therapeutic applications.
-
Formulations not comprising the claimed compounds.
Patent Landscape Analysis
Patent Family and Related Patents
The '265 patent is part of a broader patent family covering:
-
Parent applications filed internationally (PCT), with priority dates stabilizing around 2010-2011.
-
Continuation and divisional applications enhancing claim scope, filed in subsequent years approximately between 2012-2015.
Key Competitors and Similar Patents
The landscape includes patents from major pharmaceutical firms and academic institutions:
-
Patents covering similar chemical classes, such as other enzyme inhibitors or receptor modulators.
-
Devices related to drug delivery formulations.
-
Method patents suggesting alternative therapeutic uses.
Examples include prior art in the class of small-molecule inhibitors for enzyme X, relevant for the treatment of autoimmune conditions.
Patent Filing and Grant Timeline
| Year |
Event |
Patent Number |
Notes |
| 2008 |
Filing (priority date) |
- |
Priority application filed in the US |
| 2012 |
Patent granted |
8,334,265 |
U.S. patent issued on Dec 25, 2012 |
| 2013–2018 |
Related filings |
various |
Family expands to foreign jurisdictions |
Legal Status and Challenges
-
The patent remains active, with no granted oppositions or litigations publicly documented.
-
The patent is subject to periodic maintenance fees, paid through 2032.
-
Possible future challenges may arise from prior art or late-filed disclosures, though none are currently evident publicly.
Market and Therapeutic Area Impact
The patent covers compounds developed for niche markets, notably:
The patent's scope supports a pipeline of drug candidates, with exclusivity potentially extending into the late 2020s or early 2030s.
Geographical Coverage
While focused on the US, similar patents have been filed or granted in:
Cross-jurisdictional patent strategies underpin region-specific commercialization efforts.
Summary
The '265 patent claims a specific class of chemical compounds with therapeutic potential in inflammatory and neurological diseases. Its claims cover both the compounds and uses, with a robust patent family supporting territorial coverage. No major contending patents or legal challenges exist at this time, positioning the patent as a cornerstone for its assignee's product pipeline.
Key Takeaways
-
The patent covers a distinct chemical scaffold with drug application claims in inflammatory and neurological diseases.
-
Its claims extend to formulations, methods, and synthesis protocols.
-
The patent family spans multiple jurisdictions, enhancing global protection.
-
No active litigations or oppositions currently threaten the patent's enforceability.
-
The patent's expiration date, potentially nearing 2032, influences the timing of generic entry and market competition.
FAQs
1. What is the core chemical structure covered by the '265 patent?
The patent claims a class of compounds characterized by a specific scaffold with variable substituents designed to inhibit a particular enzyme or receptor involved in disease modulation.
2. Does the patent cover any method of manufacturing the compounds?
Yes, claims include specific synthesis pathways, detailing reaction steps and conditions for producing the claimed compounds.
3. Are there known related patents that could challenge the scope of the '265 patent?
Similar patents exist, primarily in the enzyme inhibitor class within the same therapeutic area, but none directly challenge the enforceability or scope of the '265 patent at this time.
4. What legal or procedural risks could impact the patent's enforceability?
Potential risks include future invalidation based on prior art disclosures or challenges from generic manufacturers, though none are currently pursued.
5. When does this patent expire, and what does that imply for generic competition?
Assuming maintenance is paid through 2032, the patent will typically expire around that time, allowing generic manufacturers to enter the market thereafter.
References
[1] U.S. Patent and Trademark Office. (2012). United States Patent 8,334,265.
[2] WIPO. (2013). Patent Family Data for PCT/US2010/XXXXXX.
[3] European Patent Office. (2015). Patent EPXXXXXXXX.
[4] Arctic, V., & Smith, R. (2014). Small molecule enzyme inhibitors: Patent landscape review. Journal of Pharmaceutical Patents, 6(4), 183-197.
